Twitter-Delivered CME/CE on
Oncology from @onc_ce
Clinical trial data now exit the research facility and enter the practice landscape at unprecedented speed and volume, and the arrival of COVID-19 has not slowed this rapid flow of information. In fact, the pandemic has shifted the release of data to even more accessible digital formats. At this point, clinicians who manage cancer and who hope to stay current and apply new research to their daily practice cannot do so on their own; they benefit from an expert’s interpretation and distillation of data as they carry new information from conference to bedside. The need for distilled information presented in an applicable format has risen faster than ever.
The heterogeneity seen in various tissue tumor types reveals a need for ever-more individualized approaches that targets molecular subtype, genetic mutations, and immunological profile for each patient. Our accredited tweetorial feed, with each program authored by international experts, provides a forum for interaction, communication, and education for all healthcare providers with an interest in cancer.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
ESMO22: Updates on ADCs in Development for Lung Cancer
2) Now we are covering @myESMO #ESMO22 updates on #ADCs in development for #LungCancer #LCSM. Our author is Antonio Passaro MD PhD (@APassaroMD)...
A Review of Updates to NCCN Evidence-based Guidelines in Advanced Ovarian Cancer
2) Earn 0.5hr 🆓CE/#CME credit w/ this 🧵! @onc_ce is your ONLY source for serialized #accredited CE/#CME #tweetorials in #oncology. This program is...
PARP Inhibitors in Ovarian Cancer: Shared Decision-making, Mitigating AEs, & Managing Disparities in Access
2) @onc_ce is your ONLY source for serialized #accredited CE/#CME #tweetorials in #oncology. This program is supported by an educational grant from...
ESMO22 updates on HER2 mutant Lung Cancer
2) Now we are covering @myESMO #ESMO22 updates on #HER2 mutant #LungCancer #LCSM. Our author is Antonio Passaro MD PhD (@APassaroMD) from...
A Scientific Analysis and Clinical Trial Review of PARP Inhibitors for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
2) @onc_ce is your ONLY source for serialized #accredited CE/#CME #tweetorials in #oncology. This program is supported by an educational grant from...
KRAS mutations and cancer data from WCLC22
2) Now we are covering @IASLC #WCLC22 updates on #KRAS_mutated #LCSM! Our author is Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare...
KRAS Mutations and Cancer Data from ASCO
2) Now we are covering @ASCO updates on #KRAS-mutated #cancers! Our author is #ASCO22 #FeaturedVoice Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc...
Relapsed Refractory Multiple Myeloma: Biomarkers and Treatment Options
1) Welcome to the next installment of our key #oncology meeting highlights via #accredited #tweetorials from @onc_ce, your new (& only) home for...
Emerging therapies in relapsed and refractory myeloma
1) Welcome to the next installment of our key #oncology meeting highlights via #accredited #tweetorials from @onc_ce, your new (& only) home for...
Key Advances in Multiple Myeloma Therapy: BCMA x CD3 Bispecific T-Cell Engagers / Antibodies Trials from #ASH2021
1) Welcome to the next installment of our key #oncology meeting highlights via #accredited #tweetorials from @onc_ce, your new (& only) home for...
@ONC_CE on Twitter
Your only source for ACCREDITED SoMe-delivered serialized professional oncology education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @onc_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.